Two Seas Capital LP recently announced the acquisition of new stake in Esperion Therapeutics Inc. (NASDAQ:ESPR). The institutional investor has increased its shareholding in the Healthcare company by 160.79% to 7.67 million shares with purchase of 4.73 million shares. This fresh investment now brings its stake to 6.75% valued currently at $10.2 million. In addition, Millennium Management LLC raised its holdings by 2.45 million to 5.79 million shares. And The Vanguard Group, Inc. has lifted its position by 11.28% or 0.48 million shares – to 4.72 million shares.
Currently, there are 113.72M common shares owned by the public and among those 112.81M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 33 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 17 of these insider trades were purchases, accounting for 286,561 shares. Insider sales of the common stock occurred on 16 occasions, with total insider shares sold totaling 37,542 shares.
The top 3 mutual fund holders in Esperion Therapeutics Inc. are Wasatch Ultra Growth Fund, BB Biotech AG, and Vanguard Total Stock Market ETF. Wasatch Ultra Growth Fund owns 4.68 million shares of the company’s stock, all valued at over $6.23 million. The company bought an additional 1.09 million shares recently to bring their total holdings to about 4.12% of the shares outstanding. Vanguard Total Stock Market ETF now owns shares totaling to 2.37% of the shares outstanding.
However, the script later moved the day high at 2.1700, up 15.93%. The company’s stock has a 5-day price change of 49.65% and 70.16% over the past three months. ESPR shares are trading -66.13% year to date (YTD), with the 12-month market performance down to -63.93% lower. It has a 12-month low price of $0.70 and touched a high of $7.41 over the same period. ESPR has an average intraday trading volume of 4.26 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 49.86%, 91.73%, and 41.12% respectively.
Institutional ownership of Esperion Therapeutics Inc. (NASDAQ: ESPR) shares accounts for 78.03% of the company’s 113.72M shares outstanding. Mutual fund holders own 19.86%, while other institutional holders and individual stakeholders account for 53.32% and 14.03% respectively.
It has a market capitalization of $239.95M and a beta (3y monthly) value of 0.59. The earnings-per-share (ttm) stands at -$2.37. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.18% over the week and 10.37% over the month.
Analysts forecast that Esperion Therapeutics Inc. (ESPR) will achieve an EPS of -$0.43 for the current quarter, -$0.38 for the next quarter and -$0.03 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.62 while analysts give the company a high EPS estimate of -$0.29. Comparatively, EPS for the current quarter was -$0.76 a year ago. Earnings per share for the fiscal year are expected to increase by 43.79%, and 98.27% over the next financial year. EPS should grow at an annualized rate of 16.90% over the next five years, compared to 12.80% over the past 5-year period.
